ABSTRACT
AIM: To evaluate the comfort and visual performance of Rose K2 soft contact lenses in patients with keratoconus.METHODS: Fifty eyes of 50 participants were included in this cross-sectional study.Each participant received a full ophthalmologic examination involving refraction,uncorrected visual acuity (UCVA),best spectacle corrected visual acuity (BCVA),slit-lamp biomicroscopy-fundoscopy,break-up time (BUT),corneal topography,and contrast sensitivity.After contact lens was fitted best contact lens corrected visual acuity (BCLCVA),contrast sensitivity,and comfort rating via visual analogue scales (VAS) were performed.RESULTS: The mean age was 26.2±6.0 (range: 16 to 39)y.The mean logMAR UCVA,BCVA,and BCLCVA with Rose K2 soft (in order) were 0.61±0.37 (range: 0.15-1.3),0.42±0.32 (range: 0-1.3),and 0.18±0.20 (range: 0-1.3).There were significant increases in visual acuities with contact lenses (P < 0.05).The mean contrast sensitivity scores were significantly better with both contact lens in mesopic and photopic conditions (P <0.05).The mean VAS score was 8.02±1.64 (range: 5-10) for Rose K2 soft.CONCLUSION: Rose K2 soft contact lens can improve visual acuity,contrast sensitivity with comfort in patients with keratoconus.
ABSTRACT
Aims: To evaluate the efficacy and safety of intravitreal bevacizumab injections on macular edema secondary to retinal vein occlusion. Study Design: Retrospective case series. Place and Duration of Study: Department of Retina, Beyoglu Eye Training and Research Hospital, between July 2012 and July 2013. Methodology: Forty two eyes (22 CRVO and 20 BRVO) were included in this study. Follow up time was a year for all patients. All patients were newly diagnosed and 3 intravitreal bevacizumab injections are used monthly and additional injection is used as needed. Scatter laser photocoagulation is used after macular edema disappears in all patients. Macular thickness was measured via spectral-domain OCT at baseline, at month 6 and at month 12. Results: The mean age of the patients was 52.4±16.2 years (range 22 – 74 years). The central macular thickness improved from 684±196 μm at baseline to 220 ± 102 μm at month 6 (p<0.001) and to 214±112 μm (p<0.001) at month 12. Best-corrected visual acuity (BCVA) at baseline improved from 1.0±0.4 logMAR to 0.6±0.4 logMAR (p<0.001) at month 12. Conclusion: Intravitreal bevacizumab injection is effective to treatment of macular edema secondary to retinal vein occlusion. 3 monthly injections and as needed regimen is effective in one year follow up time.